Fluoxymesterone Therapy in Advanced Breast Cancer

Abstract

ANDROGENIC hormones have been effectively employed in the therapy of advanced breast cancer. Objective improvement occurs in approximately 25 per cent of patients with osseous metastases, with a lower rate of response in patients with soft-tissue lesions.1 Since the effects of castration in premenopausal women are far superior to those of androgenic therapy, the male hormones have been employed primarily for women of postmenopausal age. A continuing search for more effective androgenic compounds is under way. Testosterone propionate, administered intramuscularly in three divided doses of 150 to 300 mg. weekly, has become the standard agent in the evaluation by comparison . . .